Answers are grounded in this paper and cite their sources.
Metabolomic profiling uncovers metabolic signatures in Fabry nephropathy, suggesting new early biomarkers for kidney damage.
Fabry disease is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to deficient α-galactosidase A activity and accumulation of globotriaosylceramides in multiple organs, including kidneys. Fabry nephropathy (FN) contributes to morbidity and mortality, as kidney dysfunction increases the risk of damage to other organ systems. Current biomarkers reflect only late-stage kidney damage, emphasizing the need for early, non-invasive biomarkers of kidney involvement.
No takes yet. Share an insight, caveat, or question.
Breznik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: